Connect with us

Health

N.I.H. Bans New Funding From U.S. Scientists to Partners Abroad

Published

on

N.I.H. Bans New Funding From U.S. Scientists to Partners Abroad

The National Institutes of Health will no longer allow American scientists to direct its funding to research partners overseas, casting doubt on the future of studies on subjects including malaria and childhood cancer.

Dr. Jay Bhattacharya, the new director of the N.I.H., announced the policy on Thursday, the same day Dr. Matthew J. Memoli, the principal deputy director, blasted these so-called subawards in an email obtained by The New York Times.

“If you can’t clearly justify why you are doing something overseas, as in it can’t possibly be done anywhere else and it benefits the American people,” Dr. Memoli wrote, “then the project should be closed down.”

The new restrictions, which will apply to domestic subawards as well in the future, come amid deep reductions in N.I.H. funding and the freezing of federal grants at many top universities, along with executive orders seeking to reshape the nation’s scientific agenda.

On Monday, President Trump signed an executive order restricting a type of experimentation that can make pathogens more dangerous to humans, and ending support for the so-called gain-of-function research in countries like China.

Advertisement

Researchers funded by N.I.H. grants have historically used subawards to facilitate international collaborations, which are essential for studying conditions like childhood cancer or illnesses like malaria and tuberculosis that are not prevalent in the United States.

The subawards are legal and financial agreements made between the grant recipients and their overseas partners. The practice is used throughout the federal government and is not unique to the N.I.H.

But it has come under fire in recent years because of lax reporting and tracking of funds. After a critical report by the Government Accountability Office in 2023, the N.I.H. put stricter monitoring requirements in place.

Advocates for scientific and medical research said that as science has become more complex, collaborative initiatives that draw participants and scientists from around the world have become more critical.

“Competitive science requires a team approach,” said Dr. E. Anders Kolb, chief executive of the Leukemia & Lymphoma Society. “There’s no one lab or institution or investigator that has all of the tools necessary to solve the very complex questions that we’re asking.”

Advertisement

Many of these studies require a large number of subjects. For example, as scientists are able to define types of childhood cancers more precisely, Dr. Kolb said, “you get into increasingly smaller and smaller subsets of disease.”

“So if you want to run a clinical trial of a new therapy that may benefit those children, it could take decades to complete a trial if you only enroll children in the U.S.,” he added. “When we collaborate with our international partners, we can finish these trials much more quickly and get the therapies to children as soon as possible.”

In announcing the new directive, Dr. Bhattacharya cited recent Government Accountability Office reports that have been critical of funding given to international universities and laboratories, as well as businesses.

The issues highlighted by the G.A.O. reports “can lead to a breakdown in trust and potentially the security of the U.S. biomedical research enterprise,” Dr. Bhattacharya added.

N.I.H. spending on these international groups is difficult to track, one of the faults noted by the G.A.O. The journal Nature, which first reported the new policy, estimated the total at approximately $500 million a year.

Advertisement

Dr. Monica Gandhi, a professor of medicine at the University of California, San Francisco, has N.I.H. funding to study H.I.V. prevention and treatment in Kenya and South Africa, work that will be affected by the new policy.

Researchers like her must provide detailed information about international subawards when they apply for their grants, she said, including justifications for using a foreign entity and for each aspect of the budget.

International partners must now provide access to their lab notebooks, data and other documentation at least once a year, Dr. Gandhi noted. All of the expenditures are tracked on a system called the Foreign Award and Component Tracking System, or FACTS, she said.

“It’s very rigorous, as it should be when you’re using taxpayer dollars,” Dr. Gandhi said.

“Every year when you put in your progress report, you account for every penny that was spent at the foreign site — where it went, how much to lab tests, how much was paid investigators, every aspect.”

Advertisement

It wasn’t immediately clear how the new policy would be implemented. The N.I.H. did not respond to requests for additional information.

The N.I.H. will not retroactively halt foreign subawards already in place “at this time” and will continue to make awards directly to international groups, the agency’s statement said.

But the new policy will forbid new competing awards and noncompeting awards to be reissued if they propose subawards to foreign institutions.

“If a project is no longer viable without the foreign subawards, N.I.H. will work with the recipient to negotiate a bilateral termination of the project,” the statement said.

The new policy appeared to be somewhat less draconian than the summation put forth by Dr. Memoli in his internal email, which threatened immediate action to shut down or pause international sites.

Advertisement

“Subawards to foreign sites can’t continue,” he wrote. “This has been horribly mismanaged for years and it has been completely irresponsible. We must take immediate action. If a study has a foreign site we need to start closing it down or finding a different way to fund it that can be tracked properly.”

G.A.O. reports that had criticized various federal departments for lax reporting had called for improving oversight. But the office did not recommend terminating such funding altogether.

In 2023, a G.A.O. report reviewed $2 million in direct awards and subawards, most of it from the N.I.H., given to three Chinese research institutions, including the Wuhan Institute of Virology, between 2014 and 2021.

The virology institute received subawards from the University of California, Irvine, and from the nonprofit group EcoHealth Alliance. The alliance’s work with Chinese scientists led former President Joseph R. Biden Jr. to suspend its funding last year. The Trump administration recently changed the government portal for Covid information with a website suggesting that the new virus originated in a lab in Wuhan.

The G.A.O. report said that N.I.H. oversight didn’t always ensure that the foreign institutions complied with terms and conditions, including biosafety requirements.

Advertisement

One reason expenditures were hard to track was because of a federal government policy that required reporting subawards only of $30,000 or more, another G.A.O. report said.

That report examined some $48 million in N.I.H. and State Department funding that went to Chinese businesses and research institutions between 2017 and 2021, including one project to study diseases that are transmitted by insects, like malaria.

It found that “the full extent of these subawards is unknown,” and that data was incomplete and sometimes inaccurate, because so many expenditures were exempt from reporting.

Apoorva Mandavilli contributed reporting.

Advertisement

Health

With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win

Published

on

With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win

Over lunch at his golf club in Jupiter, Fla., on the first Saturday of May, President Trump got an earful from a group of tobacco executives and lobbyists unhappy with the way the Food and Drug Administration was regulating their industry.

Eventually Mr. Trump had heard enough. He interrupted the conversation to call Dr. Marty Makary, the F.D.A. commissioner.

No answer.

Furious, the president then dialed Dr. Makary’s boss, Health Secretary Robert F. Kennedy Jr., and another top health official, Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services. He complained to them about the F.D.A.’s regulation of e-cigarettes, according to three people briefed on the meeting who were not authorized to discuss it.

The message was received. Less than one week later, the executives got what they wanted.

Advertisement

On Friday, the F.D.A. issued new guidance that could pave the way for major tobacco companies to begin selling flavored vapes and to snare a chunk of the $6 billion e-cigarette market away from illegal Chinese competitors. The new policy bypassed the F.D.A.’s regular rule-making process.

In the intervening week, Dr. Makary continued to argue against approving flavored vapes as support from Mr. Kennedy and others collapsed around him. Health and Human Services Department staff began to draft the new plan, according to two people familiar with the events.

On Tuesday, Dr. Makary resigned, telling associates he could not in good conscience remain the head of an agency that backed such a policy.

Though there is no definitive evidence linking the new guidance to donations or lobbying, the episode represented a clear pivot in the federal government’s longtime approach to the tobacco industry.

Since the 1990s, when states extracted vast payments and other concessions from the major cigarette companies in a nationwide legal settlement, Big Tobacco has been in retreat. Cigarette sales have plummeted, and regulations have mounted as consumers and administrations from both parties embraced public health consensus about the dangers of smoking and nicotine addiction.

Advertisement

Mr. Trump’s first administration initially continued the trend, proposing further restrictions on cigarettes and moving to outlaw flavored vapes over concerns that their rising popularity threatened the health of a generation of adolescents.

But since then, Mr. Trump has enthusiastically welcomed the financial support of the tobacco industry and has courted e-cigarette users as a political constituency.

The new vaping guidance highlights Mr. Trump’s willingness to use his executive authority to prioritize the causes of major corporate donors over public health concerns, taxpayer interests and the judgment of experts, sometimes including those in his own administration.

The president has developed a close relationship with tobacco companies including Altria and Reynolds American, which have donated millions of dollars to his political groups and projects, including his proposed White House ballroom. Their executives attended the lunch at the president’s golf club.

The Department of Health and Human Services, which oversees the F.D.A., referred requests for comment to the White House.

Advertisement

Kush Desai, a White House spokesman, said in a statement that Mr. Trump has pushed to expand access to vapes to help Americans trying to quit smoking.

“The only guiding factor behind the Trump administration’s health policymaking is gold standard science,” Mr. Desai said.

Reynolds American and Altria did not respond to questions about their lobbying or the conversation at the lunch.

It was attended by Jeff Raborn, a top executive at Reynolds, and Phil Park and Todd Walker of Altria, according to the people familiar with the meeting. Also attending were Brian Ballard and Rich Haselwood, lobbyists for the firm Ballard Partners, which represents Reynolds and helped marshal a sophisticated and expensive influence campaign that culminated in the new vaping guidance. Mr. Ballard is a top fund-raiser for Mr. Trump. Mr. Haselwood had been an in-house lobbyist at Reynolds before joining Ballard Partners this year.

A spokesman for Ballard Partners declined to comment.

Advertisement

While public health experts consider e-cigarettes a less harmful alternative to tobacco-burning cigarettes, the new guidance circumvents a scientific review process the F.D.A. had previously defended up to the Supreme Court. The disregarded procedures were meant to ensure approval of only those products shown in studies to help cigarette smokers transition to vapes without attracting a new generation of nicotine users.

The guidance also could allow higher nicotine levels in nicotine pouches. It includes a pledge to prioritize efforts to stop the import of illegal foreign vapes, an idea that has bipartisan support in Congress.

Taken together, the policy changes could help companies like Altria and Reynolds gain market share considered central to the survival of the industry.

The market for vapes and nicotine pouches, like Zyn, is about 30 million people in the United States, on par with the number of cigarette smokers. While the nicotine pouch market is rapidly growing, cigarettes still account for about $50.8 billion, or nearly 70 percent of the annual tobacco sales in the United States, according to a Goldman Sachs research report. Vape sales have lagged amid competition from illicit products.

In recent years, the F.D.A. has moved glacially to approve e-cigarettes, authorizing only those in tobacco or menthol flavors, including some sold by Reynolds and Altria. Unapproved Chinese vapes have poured into the United States, feeding a thriving illicit market with flavors like peach slush and watermelon ice. Last year, industry executives have said, illicit fruit-flavored vapes made up 60 percent of the e-cigarette market.

Advertisement

When Mr. Trump mounted his bid to return to the White House, some in the tobacco industry went all in, hoping he would loosen regulations on vapes and abandon plans by the Biden administration to ban menthol cigarettes and crack down on other cigarette sales.

Mr. Trump in some ways makes for an unlikely savior for the tobacco industry. He has never smoked, but he pledged during his 2024 campaign to “save vaping again.”

Through a subsidiary, Reynolds, which is the biggest seller of menthol cigarettes, donated $10 million to a super PAC backing Mr. Trump’s campaign, according to campaign finance filings. There is no public record of the subsidiary donating to groups supporting Mr. Biden or the campaign of former Vice President Kamala Harris.

Mr. Ballard, whose firm has been paid more than $4.4 million by Reynolds since the beginning of 2017, arranged for Mr. Trump to have dinner during the campaign with Reynolds executives in New York, according to a person familiar with the interactions. The executives urged Mr. Trump to oppose the menthol cigarette ban and expressed concern about Chinese vapes.

Reynolds executives including Mr. Raborn and Mr. Haselwood were such a presence around the campaign that Mr. Trump took to calling them “my tobacco guys,” according to the person familiar with the interactions and a book coauthored by a New York Times reporter and published last year.

Advertisement

When Mr. Trump won, the rest of the industry jockeyed to show support.

Altria donated $1 million to his inaugural committee; the Vapor Technology Association donated $1.25 million; and a subsidiary of Philip Morris donated $500,000.

On Mr. Trump’s second full day in office, his administration withdrew the proposed ban on menthol cigarettes, an initiative the Biden administration had already mostly abandoned. Mr. Trump’s team also set aside a Biden-era proposal to sharply restrict nicotine in cigarettes, an effort meant to speed the transition away from a product known to be deadly.

In applauding the withdrawal of the menthol ban, Billy Gifford, the chief executive of Altria, told investors on an April 2025 earnings call that “we’re hopeful that that activity and momentum continues.”

The courtship intensified.

Advertisement

Reynolds pitched in another $3 million to a different Trump-backed super PAC, while Altria and Juul each donated $1 million.

And Reynolds and Altria each donated to the effort to raise private funds to build a new White House ballroom. Mr. Raborn of Reynolds and Mr. Walker of Altria were invited to a dinner at the White House in October for donors who gave $2.5 million or more, as was Mr. Ballard.

Tadeu Marroco, the chief executive of British American Tobacco, which owns Reynolds American, predicted to investors earlier this year that the Trump administration would clamp down on illegal vapes, saying “it’s very encouraging, the signs that the new administration is giving to address that.”

The companies’ lobbying strategy also has reached into the states, where they are pushing for so-called “registry laws” — of which there are now more than a dozen including in Florida, Virginia and Pennsylvania. Many of those laws restrict e-cigarette sales to only vapes on a list from the F.D.A.

The guidance released last week said it would create such a list.

Advertisement

Sheryl Gay Stolberg contributed reporting.

Continue Reading

Health

First clade I mpox case confirmed in Connecticut after patient traveled to Western Europe

Published

on

First clade I mpox case confirmed in Connecticut after patient traveled to Western Europe

NEWYou can now listen to Fox News articles!

A case of clade I mpox — a more virulent version of the virus that causes monkeypox, according to the Centers of Disease Control and Prevention (CDC) — has been confirmed in the U.S., as global health officials also monitor newly reported hantavirus cases in Europe.

The Connecticut Department of Public Health (CDPH) said Wednesday that the state’s first identified case of clade I mpox was detected in a person who recently traveled to Western Europe, where officials continue to monitor infectious disease activity.

The World Health Organization (WHO) has also reported new hantavirus cases in Spain and France, drawing attention to the rare but potentially severe disease, which can cause serious respiratory complications in humans.

Hantavirus is typically spread through contact with infected rodents and can lead to severe respiratory illness, though cases remain rare, according to the WHO.

Advertisement

While health officials said the mpox case “does not pose a risk to the general public,” they still encourage those who may be at risk to receive the JYNNEOS vaccine.

NEW MPOX STRAIN CONFIRMED IN US STATE FOR FIRST TIME

A pharmacist wearing a latex glove holds a photo of the mpox virus, which can spread through close, intimate contact with an infected person. (iStock)

Mpox symptoms can include fever, swollen lymph nodes and a characteristic rash, according to CDC.

“Mpox hasn’t gone away, and we want people to be protected, especially as many in our community prepare for travel, festivals, and gatherings this summer,” CDPH Commissioner Dr. Manisha Juthani said in the release.

Advertisement

“The vaccine is safe, effective and widely available. Completing the two-dose series is the best way to protect yourself and your partners.”

HANTAVIRUS DEATHS ON CRUISE SHIP HIGHLIGHT DANGERS OF RODENT-BORNE DISEASE

Clade I mpox, a newer strain of the virus, first appeared in California in November 2024. (iStock)

Clade I and clade II mpox are genetically distinct forms of the virus with key differences in severity and geographic origin, according to the CDC and the WHO.

Clade I, historically identified in Central Africa, has been linked to more severe illness and higher mortality rates, with cases often involving more widespread rashes and complications.

Advertisement

A traveler walks past a sign in a busy airport about mpox. (Yasuyoshi Chiba/AFP)

Clade II, which has circulated primarily in West Africa, is generally associated with milder disease and drove the global outbreak beginning in 2022, when most patients experienced less severe symptoms and lower hospitalization and death rates, according to the WHO.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The CDC and WHO say distinguishing between the two clades helps guide risk assessments, particularly as international travel increases.

Advertisement
Continue Reading

Health

The everyday places Americans could be exposed to hantavirus — without knowing it

Published

on

The everyday places Americans could be exposed to hantavirus — without knowing it

NEWYou can now listen to Fox News articles!

Amid the current hantavirus outbreak that started on the MV Hondius cruise ship as it sailed across the Atlantic, health experts are now examining whether Americans may be encountering the virus in everyday places without realizing it.

The rare Andes strain, which was linked to the MV Hondius outbreak, is the only known hantavirus that has the capability to spread from person to person, usually through prolonged close contact with an infected person.

Most cases of hantavirus in the U.S. occur in the desert Southwest and on the West Coast, according to Dr. Linda Yancey, an infectious disease specialist at Memorial Hermann in the Houston area.

ANDES VIRUS LINKED TO CRUISE SHIP DEATHS RAISES CONCERN OVER HUMAN-TO-HUMAN SPREAD

Advertisement

“In Texas, cases are mostly seen on the west side of the state,” she told Fox News Digital. “The strain of hantavirus native to east Texas and west Louisiana, the Bayou strain, is not as infectious in humans as the western strain, the Sin Nombre strain.”

Hantavirus is primarily spread through contact with infected rodents – primarily deer mice – and their urine, droppings or saliva. (iStock)

Hantavirus is mainly spread through contact with infected rodents – primarily deer mice – and their urine, droppings or saliva, according to the Centers for Disease Control and Prevention. 

People can become infected after breathing in contaminated particles that are stirred into the air or touching contaminated surfaces and then touching their nose or mouth. More rarely, rodent bites can spread the virus.

HANTAVIRUS OUTBREAK TIMELINE HIGHLIGHTS KEY MOMENTS IN DEADLY CRUISE CRISIS

Advertisement

Exposure is most likely when cleaning enclosed or poorly ventilated areas where rodents may nest unnoticed for weeks or months, health officials say.

Risky locations can include garages, sheds, cabins, attics, barns and crawl spaces. Storage units, stables, kitchen cabinets and spaces behind appliances if rodents are present.

CLICK HERE FOR MORE HEALTH STORIES

Rodents can also nest in unused cars, RVs, campers and boats, which can be sources of exposure when reopened.

The National Park Service says that most human cases of hantavirus occur in the spring and are linked to buildings that become heavily infested with rodents over the winter.

Advertisement

The risk of inhalation is also higher when opening buildings that have gone unused for longer periods of time, sweeping dusty floors, or moving and unpacking boxes. (iStock)

“Most people are exposed when cleaning out sheds and garages where rodents have been living,” Yancey confirmed. “You can be exposed by just the dust and droppings left behind by rodents – you don’t even need to even see the rodent to be exposed.”

The risk of inhalation is also higher when opening buildings that have gone unused for longer periods of time, sweeping dusty floors or moving and unpacking boxes, experts cautioned.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Rodent exposure is not limited to buildings. Health officials say people can also encounter hantavirus risk while handling firewood, working in rodent-prone outdoor areas or disturbing rodent nests and burrows. 

Advertisement

To prevent infection, if cleaning a structure that might have harbored rodents, Yancey recommends wearing a mask and using a diluted bleach solution to wet down any dust or loose debris.

 CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“This will help kill the exposed virus and reduce the amount of infectious dust,” Yancey said.

The CDC advises against vacuuming or sweeping rodent urine, droppings or nesting materials, as this can aerosolize the virus and increase the risk of inhalation.

A Spanish passenger boards a government plane after disembarking from the hantavirus-stricken cruise ship MV Hondius at the airport in Tenerife, Canary Islands, on May 10, 2026. (Arturo Rodriguez/AP Photo)

Advertisement

Instead, health officials recommend wearing gloves, soaking rodent droppings with disinfectant, wiping them up with paper towels, properly disposing of waste and thoroughly cleaning surfaces, followed by careful handwashing.

Some signs of rodent activity can include droppings, shredded nesting materials, gnaw marks, strong musky odors and scratching sounds in the walls or ceilings, according to public health guidance.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Dr. Marc Siegel, Fox News senior medical analyst, emphasized that hantavirus is not something that most Americans encounter in daily life, and is more prominent in certain parts of Europe and Asia.

“It is very rare in the U.S. and is seen out west, but rarely,” he told Fox News Digital. “We need to avoid overpersonalizing the risk of a very rare virus.”

Advertisement

Continue Reading
Advertisement

Trending